Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Cohen on Immunotherapy in Head and Neck Squamous Cell Carcinoma

Ezra Cohen, MD
Published: Thursday, Jul 27, 2017



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

Immunotherapy is currently used as standard of care for patients who have either recurred after curative intent therapy within 6 months of completion, or in patients who have had progressed on first-line platinum-containing therapy.



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

Immunotherapy is currently used as standard of care for patients who have either recurred after curative intent therapy within 6 months of completion, or in patients who have had progressed on first-line platinum-containing therapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x